Roche makes $350M move for DNA sequencing business

Roche ($RHHBY) struck a deal to buy DNA sequencing business Genia Technologies for up to $350 million. Mountain View, CA-based Genia is developing a single-molecule semiconductor DNA sequencing platform using nanopore technology. After failing to buy Illumina ($ILMN) in 2012 and deciding to close its 454 Life Sciences sequencing unit last year, Roche has been looking for technologies to strengthen its diagnostic business. Release | More

Suggested Articles

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.

TriNetX's platform uses EHR data to help drug developers with clinical trial protocol design and study site and participant identification.

The $58 million financing round represents biopharma industry's growing interest in genomics data.